Bayer, Hurdle launch precision health strategic partnership

Published On 2023-11-30 10:00 GMT   |   Update On 2023-11-30 12:25 GMT
Advertisement

San Francisco: Hurdle and the Consumer Health division of Bayer have launched a strategic partnership to advance consumer innovations in the emerging area of healthy aging. The partnership is designed to enhance the companies’ shared ambition to transform self-care through personalized solutions.

This alliance integrates Hurdle's cutting-edge technology with Bayer’s consumer-focused product development expertise and global footprint. Through this alliance, Bayer will sell Hurdle’s saliva-based Chronomics Biological Age Test through direct-to-consumer e-commerce, with the shared goal of advancing precision health and the science behind measuring biological age through epigenetic biomarkers.

Advertisement

“Across cultures a consistent priority for people is better managing how they age,” said David Evendon-Challis, chief scientific officer and head of R&D for the Consumer Health division of Bayer. “While aging is common to us all in terms of time, how our bodies age on the inside is unique to each person and can be impacted by many factors including environment, lifestyle and genetics. Enabling people to better understand their unique place in this journey through scientific data is the first step to helping them take proactive steps in supporting their own cellular aging process.”

Tom Stubbs, CEO of Hurdle, commented, “Our partnership with Bayer marks a significant leap in precision health. At Hurdle, we've streamlined the complex journey from biomarker discovery to consumer meaningful products, thanks to our advanced technology and extensive network. Teamed up with Bayer's unmatched expertise in consumer health, we're poised to redefine and expedite self-care solutions. Together, we're championing precision health, prioritizing both speed and individualized solutions with the goal of advancing the science behind measuring biological age.”

"Hurdle's AI-powered epigenetics and multi-omics biomarker discovery engine stands at the forefront of this partnership, echoing Bayer's strategic direction towards precision health and the deployment of digital tools that allow for smarter health choices," the release stated.

Earlier this year, Bayer launched a new business unit focused on developing new precision consumer health products.

Read also: Bayer invests 130 million EUR in new production facility for innovative parenteral products

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News